"Telomeres–the terminal caps of chromosomes–become shorter as individuals age, and there is much interest in determining what causes telomere attrition since this process may play a role in biological aging. The leading hypothesis is that telomere attrition is due to inflammation, exposure to infectious agents, and other types of oxidative stress, which damage telomeres and impair their repair mechanisms. Several lines of evidence support this hypothesis, including observational findings that people exposed to infectious diseases have shorter telomeres. Experimental tests are still needed. "
In a strange way, the interest in IMET (cancer, non-infectious) has increased with infectious disease considerations (Ebola). Geron is about to become a market leader, as ASH abstracts (Nov. 6) and ASH (Dec. 6) presentations become public information. Human survival is front and center.
"I think the Tefferi abstract will contain positive news about the IMET 23 on MF with implicit info on the IMETALSTAT 33 who we know we're only allowed to continue on IMET if they were benefiting." (from end2war).
I agree with this. I don't see how the PPS can be held down much longer.
1. "HOPING & PRAYING ASH"---That is exactly what I am doing, but I believe science, medicine and the Mayo Clinic are on my side.
2. "The best and brightest with the DEEPEST pockets"--These are the people that will be listening to all presentations at ASH, and will make their decisions accordingly.
3. "retail clowns"---They are selling, and the stock is passing into stronger, wiser hands.
The PPS will trend upward as we get closer to ASH. Dr. T's abstract around Nov. 6 will be of great interest to all parties. The ongoing relations between Geron, Mayo, the FDA, and perhaps other drug companies will be sorted out (at least in part) before ASH (Dec. 6). Geron is the "market-maker" and Mayo is the "medicine-man". Imetelstat (IMET) is the medicine and Geron is the current owner. I see nothing that is negative about IMET, so the positive news will be the major market-event that will determine the PPS.
The PPS will trend upward as we get closer to ASH. Dr. T's abstract around Nov. 6 will be of great interest. The ongoing relations between Geron, Mayo, the FDA, and perhaps other drug companies will be sorted out (at least in part) before ASH (Dec. 6). Geron is the "market-maker" and Mayo is the "medicine-man". Imetelstat (IMET) is the medicine and Geron is the current owner.
I like beaver's response. To take it a bit further, you are a very ignorant and uninformed individual. For you to be correct, all of Mayo Clinic would have to be fraudulent and corrupt. The chances of that are ZERO. Imetelstat will be categorized as a good, great or miracle drug. Geron will be merged out of existence, or will partner with a deep-pocketed drug company. The PPS is going up; the question is how high. As far as your "never $2 again guarantee", that is impossible.
Thank you for the information. This reinforces all of the hopes for IMET as a top-drug for cancer now, and ultimately for aging. Telomere-telomerase research is at the very beginning.
Follow-Up (To Blackmarango)--" ASH doesn't get the Hold lifted. Period!!!!"
***ASH will tell us where we stand as investors, relative to market forces (from lws2000).
I think that we agree that IMET has been a successful, promising, effective drug as shown by MF studies at Mayo and ASH (2013). We also agree, I believe, the liver-holds were two pronged (Mayo & Geron) and the Mayo prong-hold has been lifted. Where we can't see into the future, is the timing of the relief from the remaining Geron-FDA-prong-hold (holding the PPS below $2). I believe that the FDA, Geron and Mayo are talking to each other, and studying combined data.
ASH will ultimately be very beneficial to IMET and to future studies (in the USA, in Israel, in Europe & in Asia). My belief is that IMET, ASH, and the FDA are closely tied together in symposiums and conferences from now (middle of Oct.) until ASH presentations in Dec. Others has talked about market forces (Washington Post for example) and the effect on small biotech companies. I believe in Imetelstat, but have no idea if Geron will be merged out of existence, or be absorbed by a deep-pocketed partner. I don't believe they will try "try to go it alone", and look at Geron now as part of a marketing-sales-group, that has transferred the science & medicine to Dr. T & associates.
Nobody knows the answer to that. My guess is that if there is no negative news about IMET at ASH or before (none has been published that I know about), the ASH abstracts (early Nov.) will be the take-off-point. The MF conference (Dec. 5), around the same time as ASH, that others have referred to, will be another source of information.
PREVIOUS---I don't believe that the FDA has any reason or motive to keep Imetelstat (IMET) off of the market. In fact, I believe just the opposite, and ASH will be the vehicle for lifting all of the impediments that have been placed in IMET's way. Geron got caught in an ill-conceived and unnecessary liver hold, that may have been their own fault in part. The Mayo-Geron association, with Dr. Tefferi at the center, was put together to undo this unfortunate situation. There is every reason to believe that ASH abstracts (early Nov.) and ASH (early Dec.) will bring good news, and get the FDA off of our backs.
The "Liver-Hold" had nothing to do with the quality, safety or the effectiveness of IMET. Liver problems were on the mind of the FDA from difficulties in other (non-IMET) studies. Geron and Mayo both were caught by surprise, with Geron in the much weaker position, at the time, to respond. Mayo had the successes of their MF studies (ASH 2013). The presentations at ASH (2014), and perhaps before, will put everything into proper perspective, with IMET the likely winner.
I don't believe that the FDA has any reason or motive to keep Imetelstat (IMET) off of the market. In fact, I believe just the opposite, and ASH will be the vehicle for lifting all of the impediments that have been placed in IMET's way. Geron got caught in an ill-conceived and unnecessary liver hold, that may have been their own fault in part. The Mayo-Geron association, with Dr. Tefferi at the center, was put together to undo this unfortunate situation. There is every reason to believe that ASH abstracts (early Nov.) and ASH (early Dec.) will bring good news, and get the FDA off of our backs.
Hi Stern & Black--As others have said, "IMET works". ASH abstracts (2014) will support and expand that thought. The Geron-Mayo combination database, and the closer association of Geron and Mayo (through Dr. Tefferi) should remove all hold-problems. The outcome has to be a spike in Geron's price, similar to the rise after ASH (2013). I agree that Geron got "screwed-up" by some grouping of the FDA's low-level, trivial liver holds, market control (Washington Post article), Geron's incomplete data collecting methods, and some of the actions (or lack there of) of current management. I believe that Mayo is now effectively running the show with their successful, ongoing MF trials and studies, the FDA is surely aware of this, and Geron is deferring to more powerful forces (Mayo and the FDA). ASH (2014) has the answers, with the abstracts available in about 4 weeks. Patience is now easier.
I am waiting for ASH for the final approval of IMET in the eyes of the investment community as well as the medical community. There has been nothing to refute the good news from ASH (2013), which should be strengthened and reinforced at ASH (2014). The liver considerations had little or nothing to do with IMET, and seem to be a non-event. Only negative data coming from the Mayo MF studies can impede IMET's progress. There is none that I am aware of. Some small biotech companies are being strictly controlled by wealthy hedge funds, and high frequency traders according to the Washington Post. That should end with good news from ASH (2104), and the FDA should follow by lifting any lingering holds.
It is the Mayo successes, in their MF studies, that hold all the reasons for investing in IMET (telomeres-telomerase). We are all waiting for ASH to confirm the "good news". There is a general belief by many that Mayo can be trusted fully, while Geron less so. This seems to be reflected by the FDA.
It seems to me that Imetelstat has already been proven (remissions, improvements) by the last ASH conference (New Orleans, 2013). The holds, from some liver considerations, have already been discounted in the medical world. ASH (2014) can only reinforce the viability and potential of IMET. The PPS is a passive indicator of the medical realities, and, as the Washington Post article has told us, as a small biotech company it is subject to extreme manipulations, that may be illegal.
Hi blackmarango---The "m---lunatic" says, "I wholly concur that GERN is going to gap up explosively." I happen to agree with him about that, but I agree with you about GERN's questionable management, that is holding the PPS in check. Thanks for the interesting dialogue about IMET, with which I also usually agree. ASH and a bit of time should settle these differences.---lws2000.
There is no way that Imetelstat can fail at this late date. Mayo and Geron have combined their data in such a way that the FDA cannot ignore the successes, including improvements, remissions and cures. ASH will amplify these successes.
From Black---"lws: I think that you are putting too much faith in the ASH. Anyone who has actually studied the results and findings of Dr. T knows that IMET has produced some very remarkable results and its full potential isn't currently known"
The world is not convinced that IMET has "some very remarkable results ". I am hoping that ASH will end that debate. Geron is a different question.